Is IBRX a Buy or a Sell? The Bull and Bear Case (2026)
Last updated July 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for ImmunityBio (IBRX) rests on Anktiva revenue ramp: Net product revenue grew roughly 700% in full-year 2025 to about ~$113M, and Q1 2026 revenue rose about 168% year over year to roughly ~$44M. The bear case rests on iBRX carries the full risk profile of an unprofitable commercial-stage biotech. Analysts covering it publish targets from $12.00 to $15.00 against a $6.86 price, so even the professionals disagree by 24% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
ImmunityBio (IBRX) is a clinical- and commercial-stage immunotherapy company built around Anktiva (nogapendekin alfa inbakicept), an IL-15 receptor agonist immunotherapy. Its lead approved use is in combination with BCG for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), and the company is pushing label expansions into BCG-naive bladder cancer and lung cancer while building out global commercial partnerships across roughly 33 to 34 countries. The founder and largest shareholder, Patrick Soon-Shiong, remains central to the story and its strategy. The investment picture is a classic early-commercial biotech: revenue is growing very quickly but from a small base, the company is still deeply unprofitable, and it burns cash each quarter, which has historically been funded through equity and financing that dilutes existing holders. As of JULY 2026 the market value (roughly ~$8.7B) is large relative to trailing revenue (~$113M for full-year 2025), so the price embeds substantial expectations for future label expansions and adoption. That combination of approved-product traction plus a big valuation on small sales makes IBRX a high-variance name whose outcome hinges on execution, regulatory decisions, and access to capital.
The bull case: what would have to be true for $15.00
The most optimistic published target on IBRX is $15.00, +118.7% from the $6.86 price as of July 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. Anktiva revenue ramp
Net product revenue grew roughly 700% in full-year 2025 to about ~$113M, and Q1 2026 revenue rose about 168% year over year to roughly ~$44M. Continued physician uptake in BCG-unresponsive NMIBC is the core near-term growth engine. The base is still small, so percentage growth can stay high while absolute dollars remain modest.
2. Label and indication expansion
ImmunityBio is pursuing expansion into BCG-naive NMIBC, with a pivotal trial reported as fully enrolled and an sBLA submission targeted for 2026, plus early data in lung cancer. Each additional approved use widens the addressable population. These expansions are also the main justification for the current valuation, so timing and outcomes matter a great deal.
3. Global commercial partnerships
The company has signed distribution and approval arrangements spanning roughly 33 to 34 countries across multiple regulatory jurisdictions. International approvals can add revenue without ImmunityBio bearing the full commercial cost. Execution across many geographies and partners adds complexity and uncertainty.
4. Broader immunotherapy pipeline
Beyond Anktiva monotherapy combinations, ImmunityBio is exploring NK-cell therapy and other immunotherapy combinations across solid tumors. A wider pipeline offers optionality if additional programs advance. Most of these remain early and unproven, so they are potential upside rather than current value.
The bear case: what would have to be true for $12.00
The most pessimistic published target is $12.00, +74.9% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks ImmunityBio is worth if the risks below bite instead of the drivers above.
IBRX carries the full risk profile of an unprofitable commercial-stage biotech. It reported large net losses (a Q1 2026 net loss of roughly ~$633M versus about ~$130M a year earlier, inflated by non-cash items, with an adjusted net loss near ~$86M) and burns roughly ~$75M of operating cash per quarter, which repeatedly requires financing that can dilute existing shareholders. Its market value (about ~$8.7B) is very large relative to trailing revenue (~$113M), so any slowdown in adoption, a negative regulatory decision, competitive pressure, or a difficult capital raise could move the stock sharply. Single-drug concentration and dependence on continued Anktiva execution compound these risks.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding IBRX already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on IBRX
4 analysts cover IBRX, with an average target of $12.75 (+85.9% against $6.86) and a split of 4 buy, 0 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the IBRX forecast and price target page.
How is IBRX valued? (as of JULY 2026)
Snapshot for IBRX as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (FY2025): ~$113M net product revenue
- Revenue growth (Q1 2026 YoY): ~168%
- Q1 2026 net product revenue: ~$44M
- Cash and marketable securities (Mar 31, 2026): ~$381M
- Quarterly operating cash burn: ~$75M
- Market capitalization: ~$8.7B
The valuation is striking: a multi-billion-dollar market value against roughly ~$113M of trailing revenue implies a very high price-to-sales multiple and prices in significant future growth. The company is not profitable and funds ongoing losses partly through financing, so cash runway and dilution are central to the story. These figures are as of JULY 2026 and shift with each quarterly report and any capital raise.
How do you decide if IBRX is a buy?
Rather than asking whether IBRX is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold IBRX indirectly through an index or sector ETF before adding more.
What would change your mind on IBRX
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: Anktiva revenue ramp stalls in the reported numbers rather than in the narrative around them.
- Bear case breaks if: iBRX carries the full risk profile of an unprofitable commercial-stage biotech fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the IBRX stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about IBRX against your real portfolio and see your actual exposure before deciding.
Investing in ImmunityBio with AI
Connect the broker you already use and ask Walnut's AI how IBRX fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
Is IBRX a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on Anktiva revenue ramp, with revenue (fy2025) at ~$113M net product revenue. The bear case rests on iBRX carries the full risk profile of an unprofitable commercial-stage biotech. Analysts covering it are spread from $12.00 to $15.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.
Should I sell IBRX?
+
Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. IBRX carries the full risk profile of an unprofitable commercial-stage biotech. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $12.00, +74.9% from the $6.86 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.
What is the bull case for IBRX?
+
Anktiva revenue ramp. Net product revenue grew roughly 700% in full-year 2025 to about ~$113M, and Q1 2026 revenue rose about 168% year over year to roughly ~$44M. The most optimistic analyst target on IBRX is $15.00, +118.7% from the $6.86 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for IBRX?
+
IBRX carries the full risk profile of an unprofitable commercial-stage biotech. It reported large net losses (a Q1 2026 net loss of roughly ~$633M versus about ~$130M a year earlier, inflated by non-cash items, with an adjusted net loss near ~$86M) and burns roughly ~$75M of operating cash per quarter, which repeatedly requires financing that can dilute existing shareholders. Its market value (about ~$8.7B) is very large relative to trailing revenue (~$113M), so any slowdown in adoption, a negative regulatory decision, competitive pressure, or a difficult capital raise could move the stock sharply. Single-drug concentration and dependence on continued Anktiva execution compound these risks. The most pessimistic published target is $12.00, +74.9% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.
What does ImmunityBio do?
+
ImmunityBio (IBRX) is a clinical- and commercial-stage immunotherapy company built around Anktiva (nogapendekin alfa inbakicept), an IL-15 receptor agonist immunotherapy.
What would have to change for IBRX to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Anktiva revenue ramp) stalling in the reported numbers rather than in the narrative, the risk above (iBRX carries the full risk profile of an unprofitable commercial-stage biotech) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What does ImmunityBio (IBRX) do?
+
ImmunityBio is a commercial-stage immunotherapy company. Its lead product, Anktiva, is an FDA-approved IL-15 receptor agonist immunotherapy used with BCG for BCG-unresponsive non-muscle invasive bladder cancer, and the company is pursuing additional cancer indications.
Is IBRX profitable?
+
No. As of JULY 2026 ImmunityBio is unprofitable and reports large net losses while it invests in commercialization and trials. It burns roughly ~$75M of operating cash per quarter, which it has funded partly through financing that can dilute shareholders.
How fast is Anktiva revenue growing?
+
Very fast off a small base. Full-year 2025 net product revenue rose about 700% to roughly ~$113M, and Q1 2026 revenue grew about 168% year over year to roughly ~$44M. High percentage growth reflects the early stage of the launch.
Walnut is informational, not investment advice, and gives no verdict on IBRX. Analyst targets referenced here come from a July 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.